NCT02142803 2025-11-13TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid TumorsNational Cancer Institute (NCI)Phase 1 Active not recruiting50 enrolled 16 charts
NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT02327078 2025-08-14A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)Incyte CorporationPhase 1/2 Completed307 enrolled 27 charts
NCT00445965 2024-04-04Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal CancerMemorial Sloan Kettering Cancer CenterPhase 2 Completed78 enrolled 11 charts
NCT01631552 2021-08-12Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerGilead SciencesPhase 1/2 Completed515 enrolled 28 charts 2 FDA
NCT01132547 2015-07-02Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for CancerUniversity of South FloridaPhase 3 Terminated22 enrolled 9 charts
NCT00538850 2014-03-05Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainINSYS Therapeutics IncPhase 3 Completed130 enrolled 9 charts